Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

作者：Evgin Laura; Ilkow Carolina S; Bourgeois Daigneault Marie Claude; de Souza Christiano Tanese; Stubbert Lawton; Huh Michael S; Jennings Victoria A; Marguerie Monique; Acuna Sergio A; Keller Brian A; Lefebvre Charles; Falls Theresa; Le Boeuf Fabrice; Auer Rebecca A; Lambris John D; McCart J Andrea; Stojdl David F; Bell John C^*

来源：Molecular Therapy-Oncolytics, 2016, 3: UNSP 16027.

DOI：10.1038/mto.2016.27

The systemic delivery of therapeutic viruses, such as oncolytic viruses or vaccines, is limited by the generation of neutralizing antibodies. While pseudotyping of rhabdoviruses with the lymphocytic choriomeningitis virus glycoprotein has previously allowed for multiple rounds of delivery in mice, this strategy has not translated to other animal models. For the first time, we provide experimental evidence that antibodies generated against the lymphocytic choriomeningitis virus glycoprotein mediate robust complement-dependent viral neutralization via activation of the classical pathway. We show that this phenotype can be capitalized upon to deliver maraba virus pseudotyped with the lymphocytic choriomeningitis virus glycoprotein in a Fischer rat model in the face of neutralizing antibody through the use of complement modulators. This finding changes the understanding of the humoral immune response to arenaviruses, and also describes methodology to deliver viral vectors to their therapeutic sites of action without the interference of neutralizing antibody.

• 出版日期2016-11-16